ReviewNPJ precision oncology2026
Decoding the crosstalk between ubiquitination and other post-translational modifications in cancer immunity: from mechanisms to clinical prospects.
Review in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment is dynamically regulated by complex post-translational modifications (PTMs), which play pivotal roles in cancer immunity. Ubiquitination, along with other PTMs such as phosphorylation, glycosylation, and acetylation, orchestrates immune checkpoint activity and immune cell function, shaping antitumor responses. In this review, we discuss the intricate crosstalk and regulatory mechanisms between ubiquitination and other PTMs in cancer immunity. Studies have revealed that the stability and function of immune checkpoint proteins, such as PD-L1, are dynamically regulated by synergistic or competitive modifications, which directly shape the tumor microenvironment's immunological characteristics. We highlight how PTMs regulate immune cell function (e.g., T cells, NK cells, and macrophages) and key signaling pathways (e.g., STAT, type I IFN, and NF-κB) in the TME. Furthermore, we summarize potential therapeutic strategies targeting these PTMs, including small-molecule inhibitors and novel technologies (e.g., PROTACs and cell-penetrating peptides), which offer insights into overcoming immunotherapy resistance and optimizing combination therapies. Future research should explore non-classical PTMs and leverage multi-omics approaches to refine precision immunotherapy strategies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.